Drugs / GVAX Pancreas
last change Feb 2017 re-read 2 minutes ago

GVAX Pancreas

Vaccine

Developed for
malignant pancreatic neoplasm
Investigated by
Aduro Biotech, Inc. · Johns Hopkins University

Trials 1 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01417000 Sep 2011 → Oct 2016 malignant pancreatic neoplasm Aduro Biotech, Inc. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GVAX Pancreas ClinicalTrials.gov intervention name — accepted as the source's own label NCT01417000
Modality Vaccine “GVAX pancreas vaccineNCT01417000
Route Other “GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection” NCT01417000